The GLP-1 Revolution
From diabetes treatment to weight loss phenomenon — Mounjaro and Zepbound are reshaping healthcare
GLP-1 Revenue
Mounjaro + Zepbound revenue (billions)
GLP-1 Share of Revenue
How much of Lilly depends on these drugs
How a diabetes medication became the most important drug in decades
Bigger than the entire global video game industry. One drug class.
Pharma giant leading the GLP-1 revolution — Mounjaro, Zepbound
Tirzepatide (Mounjaro/Zepbound) revenue could exceed $25B annually. Gross margins above 80%. Manufacturing capacity is the only bottleneck to even faster growth.
Profitability over time
From diabetes treatment to weight loss phenomenon — Mounjaro and Zepbound are reshaping healthcare
Mounjaro + Zepbound revenue (billions)
How much of Lilly depends on these drugs
Enjoyed the Eli Lilly and Company breakdown?
Get the next one in your inbox.
Eli Lilly is a global pharmaceutical company founded in 1876. Known for pioneering insulin production, Lilly now leads the GLP-1 revolution with Mounjaro and Zepbound, becoming the world's most valuable pharmaceutical company by market cap.